Abstract 2460
Background
The main purpose of the work was to study the key exosomal factors involved in the development of hormonal resistance of breast cancer cells. The work is based on our previous data, which demonstrated the effect of exosome-mediated transferring of hormonal resistance in in vitro cultured MCF-7 breast cancer cells.
Methods
Estrogen-dependent breast cancer cells MCF-7 and the tamoxifen-resistant subline MCF-7 /T were used as an experimental model. The analysis of exosomal microRNAs was performed by HiSeq2500 and at least 5 million reads per samples were obtained. MicroRNA was extracted from by PureLink RNA Micro Kit; library preparation was carried out with NEBNext® Small RNA Library Prep Set for Illumina®. Transfection of the RNA oligonucleotides was performed using Metafectene PRO (Biontex) to result in the final RNA concentration of 50 nM.
Results
A comparative analysis of exosomal miRNAs of MCF-7 and resistant MCF-7/T cells was carried out. In total, 2588 miRNAs have been identified in the exosomes. Among them, mir-181 family, which is one of the negative regulators of estrogen-dependent growth, was identified as the group of miRs, hyperexpressed in the resistant exosomes. Following this, we analysed the role of mir-181c, one of the main members of miR-181 family, in the regulation of cell growth and hormonal response. Mir-181c transfection was found to induce the estrogen-independent growth and partial tamoxifen resistance of MCF-7 cells. The study of the signaling proteins showed that mir-181c transfection, in contrast to scrambled RNA transfection, caused the increase of the amount of Raptor, phosphorylated forms of mTOR and Akt that correlated with increased AP-1 transcriptional activity.
Conclusions
We have demonstrated the involvement of miR-181c in the development of hormonal resistance of breast cancer cells that allows us to consider mir-181 as the perspective target of the treatment of hormone- independent cancers. The research was supported by the Russian Science Foundation (19-15-00245, miRNA analysis) and RFBR (#18-29-09017, tamoxifen resistance).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation, project 19-15-00245.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4852 - Impact of routine screening and preemptive treatment on hepatitis B virus reactivation (HBVr) in patients receiving chemotherapy
Presenter: Celine Marty
Session: Poster Display session 1
Resources:
Abstract
5225 - The uptake, patient satisfaction and efficacy of scalp cooling among patients receiving chemotherapy in an Irish oncology day ward.
Presenter: William Maher
Session: Poster Display session 1
Resources:
Abstract
1901 - Placebo adverse events (AEs) in targeted and immune cancer therapy in the adjuvant and advanced setting: A systematic review and meta-analysis
Presenter: Diego Enrico
Session: Poster Display session 1
Resources:
Abstract
3258 - Reduced antibody levels and high seronegativity rates against vaccine preventable diseases pose a risk factor for infections in patients with solid and hematologic cancers
Presenter: Angela Guzek
Session: Poster Display session 1
Resources:
Abstract
3211 - Prognostic Factors Influencing Outcome After Therapy With Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin's Lymphoma
Presenter: Veselina Goranova - Marinova
Session: Poster Display session 1
Resources:
Abstract
4949 - Phase I Study of CC-90010 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
Presenter: Victor Moreno
Session: Poster Display session 1
Resources:
Abstract
2271 - Pretreatment coagulation factors related to prognosis in patients with natural killer/T cell lymphoma
Presenter: Yue Chai
Session: Poster Display session 1
Resources:
Abstract
4335 - Diffuse large B cell lymphoma in the elderly. A retrospective analysis of standard versus alternative treatments
Presenter: Irene Sillero
Session: Poster Display session 1
Resources:
Abstract
5117 - MIPI as a superior prognostic tool in Mantle Cell Lymphoma compared to monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratios
Presenter: Filipa Macedo
Session: Poster Display session 1
Resources:
Abstract
5135 - Dose adjustment of chemotherapy in aggressive lymphoma using automated and standardized analysis and evaluation of DNA double strand breaks
Presenter: Julia Schröder
Session: Poster Display session 1
Resources:
Abstract